Furthermore, treatment with the anti‐CXCL13 antibody inhibited ERK activation and slowed tumor growth in a 4T1 mouse model of breast cancer, thus providing a rationale for clinical trials targeting CXCL13.396. This evidence concerns the gene CXCL13 and neoplasm.